Business
Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Top line Data from Phase 2b FORTRESS Study of IMC-1 on Track for Q3 2022 - - Pipeline Expanded with IMC-2 as Treatment for Long COVID to be Evaluated in
About this update from Dogwood Therapeutics, Inc.
[{"type":"text","content":"\n- Top line Data from Phase 2b FORTRESS Study of IMC-1 on Track for Q3 2022 -\n\n- Pipeline Expanded with IMC-2 as Treatment for Long COVID to be Evaluated in New Exploratory Study Targeted to Commence in Q2 2022 -\n\n- Conference Call Today at 8:30 a.m. ET -\n\n ATLANTA--(BUSINESS WIRE)--\nVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases including fibromyalgia, today announced financial results for the fourth quarter and full year ended December 31, 2021.\n\nKey Highlights\n\n\nPhase 2b FORTRESS fibromyalgia study top line results on track for Q3 2022\n\n\nChronic toxicology studies, required for IMC-1 Phase 3 studies, are progressing as planned and synchronized for completion with the FORTRESS study\n\n\nRecently announced clinical development collaboration to assess therapeutic potential of IMC-2 as a treatment for Long COVID, a developing health crisis\n\n\nCash on hand of $14.0 million on December 31, 2021, provides runway through Q1 2023\n\n\n“Virios achieved many operational milestones in 2021, most notably launching recruitment and dosing in the Phase 2b FORTRESS study. We project to reach full enrollment for the trial of over 400 patients by mid-April,” said Greg Duncan, Chairman and CEO of Virios Therapeutics. “We also recently announced the expansion of our research pipeline through a collaboration with the Bateman Horne Center, a leading research center in post-viral syndromes. The focus of the collaboration is centered on conducting a new exploratory trial assessing the potential of IMC-2, a combination of valacyclovir and celecoxib, to reduce fatigue and other symptoms associated with Long COVID sequalae, which is estimated to effect up to 30% of former COVID patients.”\n\n“Our most important priority is completing the FORTRESS study, with planned reporting of top line results in Q3 2022. This study will assess the effectiveness of IMC-1 in reducing the systemic pain and other symptoms associated with fibromyalgia. Our cash on hand of $14.0 million is expected to support the Company’s operations through those important months and into the planning for a Phase 3 study in early 2023,” concluded Angela Walsh, Senior Vice President, Finance, of Virios Therapeutics.\n\nFourth Quarter 2021 Financial Results\n\nRes...